Matt McCall is pitching a “$200 into $1 million” stock idea as he tries to drum up subsribers for his NexGen Investor… and that sounds fun, right, owning a stock that goes to a million dollars per share? It probably won’t happen, of course, and I don’t know how many times it might have actually […]
Articles
There’s a clear winner in the “what readers are asking about” sweepstakes this morning, and it’s the latest pitch from Charles Mizrahi for his Park Avenue Investment Club (currently $99/yr) — so that ad must really be making the rounds, and we’ll fire up the Thinkolator to get you some answers today. The pitch is […]
Gumshoe BioDimSum II: Corralling the “A” Biotechs Plus a New Long Selection[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I feel it's a good idea to have a cluster around the gene editing companies, those based around the Jennifer Doudna and ...
Bluebird bio, you mean? BLUE has indeed been similarly teased, they use the word “genesis” in a lot of the gene edi...
$SYBX NP (yet) Thanks for that post John: here are some interesting items relating to SYBX: Interesting that the compa...
$SRNE NP Nice find Doc with $SRNE . With $JUNO and $KITE being bought out only $BLUE and $SRNE are the only remaining s...
$BLUE is an interesting company, but extracts too much mileage from too little clinical data and has a long way to go pr...
#MOTLEY FOOL pics wow, all 4 are biotechs. Bodes well for the sector! btw, Bluebird Bio appears to be located 1.4 mi...
$MOTELY Fool's top 4 BIO Pics for 2018. Just got a teaser ad for the MF Explorer investment newsletter. They are nomin...
I did something similar as well. Last week, I sold out of my positions in $BLUE, $RDUS, $CAPR and $ZFGN. I like them a...
$BLUE - Bluebird’s gene therapy shows promise in keeping lethal Lorenzo’s Oil disease in check https://endpts.c...
It seems lately my Bio portfolio is micro companies $AUPH $CAPR or very large $CELG and I’ve been looking for somethin...
$GeneEditing $CLLS $EDIT $SGMO $BLUE $CRSP A very informative compilation that compares various gene editing techniqu...
NP in $BLUE, although perusing this recommendation I wished I did! bluebird bio, Inc. (NASDAQ:BLUE) had its price targe...
$CELG $JUNO $BLUE $CLLS - a Barron's article just off the hot press: "Juno Therapeutics: Celgene’s Next Target?" ...
$ESPR long. I've been fattening up my position here. This stock reminds me of $BLUE, in that both companies got pret...
$CAR-T cell therap (a nice primer) $NVS $KITE $JUNO $BLUE "First gene therapy — ‘a true living drug’ — on th...
So it appears here that $BLUE is getting more "kick" out of their upgraded manufacturing process (they're not disclosing...
$BLUE Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug #EHA17 http://www.businesswir...
I think this is referring to Nanjing Legend, which was recently in the news for the same reason. Came out of nowhere and...
$BLUE (np) I read that" Cambridge-based bluebird bio said Tuesday that Novartis and GlaxoSmithKline will pay undisclosed...
4 Biotechs breaking out on drug development news: $BLUE $KITE $ESPR $FOLD - an interesting read from Forbes: https://...
Thanks Cleveland for all your work on this, and all the great documents you've been adding to dropbox. Hopefully the...
Dr. KSS - Quick follow up on your CAR-T space commentary that, "I love $BLUE. But ... I just don’t feel the upside rig...
We recently shared holdings with each other here and I wanted to say a few more things about that. (1) I appreciate t...
$BLUE np The offer price can't be lowered. The deal was done on December 6. It doesn't matter when the deal closes. The ...
Wondering if $BLUE will lower it's offering price. Offer at 76 but share price currently at 69. $BPMC on the other hand ...
$BLUE has proposed to undertake a secondary offering of $200 million of its common stock: CAMBRIDGE, Mass.--(BUSINESS...
Oh no Jabber...please consider keeping your $blue jewels. I sold mine in order to build a larger position of $INCY and $...
A highly informative analysis of BLUE's interim results from anti-BCMA study released today, with critical comments on t...
$BLUE announced highly favorable interim Ph1 results for its Anti-BCMA CART-T candidate, bb2121, in patients with R/R mu...
Doc and Linling (owing to your position in $BLUE), what is your opinion of information contained in today's ASH abstract...
$BLUE: Subpar results reported last December with #LentiGlobin in patients with sickle cell disease and beta-thalassemia...
$BLUE - bluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy D...
$BLUE, $MDGEF - bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherapy ...
$BLUE Webcast Wedbush PacGrow Healthcare Conference (Live) 08/17/16 at 9:10 a.m. ET http://investor.bluebirdbio.com/...
Helen Ong @Lin_ling_88 1h1 hour ago $BLUE: bluebird bio Will Make Ten Presentations at ASGCT Annual Meeting #May 4-...
Free e-mail from PropThink The biotech sector has taken a meaningful step towards making up lost ground. After consolid...
Long BLUE. I did meet a young man with Sickle Cell who was quite determined to make his own way, pay his own bills, and...
Benitec And Bluebird Bio, Gene Therapy Coming Of Age? Summary Benitec, a ddRNAi gene therapy company, announces ...
$JUNO.$KITE,$BLUE: Juno Therapeutics Inc, Kite Pharma Inc, bluebird bio Inc To Be The Next Targets Amid Acquisition Fre...
$BLUE. Bluebird Bio "today announced the pricing of an underwritten public offering of 2,941,176 shares of its common s...
$BLUE-From Schaeffer's Investment Research: BLUE has had a standout run, up almost sevenfold year-over-year. The equity...
$CELG $BLUE Celgene and bluebird bio give up on CAR-Ts, move to anti-BCMAs http://www.seekingalpha.com/news/2560416...
New Developments: $BLUE $CELG Celgene and bluebird bio to Develop Anti-BCMA Product Candidates; bluebird bio Rega...
$BLUE Form 4 bluebird bio, Inc. For: Jun 01 Filed by: Finer Mitchell H. 10K WIZARD 8:54 AM ET 6/3/2015 http://archiv...
BLUE-On fire about 189 on heavy volume: bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to devel...
Thought this might interest you all... ViewPoints: CAR-T front-runners seek to outpace emerging competition (Ref: View...
Bluebird Bio ($BLUE) has put out word that enrollment in its trials for beta-thalassemia and childhood cerebral adrenole...
Hi Corey: I am saddened to hear that but all is not lost certainly. Bluebird Bio is enrolling now for a phase 2/3 trial ...
* Bluebird Bio : Piper Jaffray raises target to $186 from $119; rating overweight Thank you Dr. KSS for your recommen...
Top twenty with ticker symbol AKAO Achaogen ARWR Arrowhead ATNM Actinium AUP Aurinia Pharmaceuticals BLCM Belli...
Here are twenty stocks reviewed positively for their science by Dr. Kss in recent articles. For many of us twenty stock...
RE: BLUE http://www.financialbuzz.com/bluebird-bio-inc-nasdaq-blue-major-catalyst-expected-in-june-247749 "Bluebird bio...
XBI HOLDINGS volume order Symbol Description Percent of Net Assets DYAX Dyax Corp 1.75% ESPR Esperion Therapeuti...
Kenny, here is a list of the companies included in the LCINDX index: Novartis Merck Amgen Bristol Myers Celgene AstraZe...
Bluebird Bio (BLUE) up over 12% today with no news I can find. Is this another possible aquisition situation like Recept...
Present state of pipeline and upcoming milestones for bluebird bio $BLUE. https://pbs.twimg.com/media/B_FP-U5UQAAFGsP...
For what it's worth (from First Call Rating update) Re: BLUE Analysts from various Brokerage Firms have rated the comp...
Re: BLUE Stock analysts at Wedbush hoisted their target price on shares of bluebird bio (NASDAQ:BLUE) to $146.00 in a r...
$BLUE (AND ISIS) get plugs from Legg Mason health care analyst Marshall Gordon in a Barron's interview from yesterday: ...
Funny, I felt the opposite way ... as a bird lover, how could I resist owning shares of bluebird bio???!?!...
The market may be down, but Dr KSS's picks are up, way up. Thank you Dr KSS, my biotech stocks are looking pretty good...
MZOR, BLUE, CANT, AZO-Benzinga's Top #PreMarket Gainers 8:13a ET December 9, 2014 (Benzinga) Print bluebird bio (NASDA...
bluebird bio Announces Data Demonstrating First Four Patients with β-Thalassemia Major Treated with LentiGlobin™ are ...
I am sentiment-long on bluebird bio ($BLUE), and suspect it will be acquired by CELG, but one reason I personally didn't...
BLUE CELGN "Coming out of this ASH meeting, expect the investor frenzy for CAR-T companies to escalate. The upcoming J...
Glenn and friends - Bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene T...
Hey guys, I am in bluebird bio (BLUE) as well. Smart people are running this company and smart people are betting on the...
Glenn, thanks for that. I'd love to hear what you and others think of bluebird bio, as it is one I am holding....
I think glorious days, days even more glorious than now, are coming for CELG. I am long Novo Nordisk, and I feel it will...
Thanks Eyedoc for your great sleuthing on Avalanche Bio. I would like to add that the CEO of this company, Tom Chalberg...
The Mar/Apr 2014 issue of MIT Technology Review says that Bluebird Bio is one of 32 companies that Third Rock Ventures f...
There was an interesting article today in The Street by Dan Rosenblum on Bluebird Bio. Their new drug Lentiglobin for...
Salix acquired Santarus earlier this year and has now done the Irish tax-inversion two-step by acquiring Cosmo. Blueb...
RNAi company bluebird Bio (BLUE) up big today ~14%...
The following info about RA Capital's holdings, as at end of 2013 may be of interest to some of you: 37 Positions as of...